Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979979 | 0.92 | CASP3 (0.61) | MAOBRAB9ANPC1CASP3MAPT | |
| SCHEMBL982779 | 0.85 | MAOB (0.61) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL978163 | 0.85 | MAOB (0.52) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL978668 | 0.85 | CASP3 (0.53) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL980408 | 0.84 | KMT2A (0.52) | MAOBRAB9ANPC1CASP3MAPT | |
| SCHEMBL981176 | 0.83 | CASP3 (0.51) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL980671 | 0.82 | MAPK1 (0.55) | MAOBRAB9ANPC1CASP3MAOA | |
| SCHEMBL978558 | 0.81 | MAOB (0.56) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL980673 | 0.81 | RAB9A (0.56) | MAOBRAB9ANPC1CASP3ADORA3 | |
| SCHEMBL980399 | 0.81 | CASP3 (0.64) | MAOBRAB9ANPC1CASP3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | MAOB 3235/4885RAB9A 3095/4885NPC1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.